Mi Hee Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mi Hee Lim has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
- Hyuck Jin Lee
Department of Chemistry Education, Kongju National University, Gongju-si 32588, Chungcheongnam-do, Republic of Korea
27 shared publications Mingeun Kim
Department of Chemistry Korea Advanced Institute of Science and Technology (KAIST) Daejeon Republic of Korea
23 shared publicationsJuhye Kang
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
21 shared publicationsEunju Nam
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
18 shared publicationsGeewoo Nam
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
17 shared publicationsJiyeon Han
Department of Chemistry Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Republic of Korea
16 shared publications
Latest Publications
- 13 October 2026
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 95, 102792
Effects of metal ions on amyloid liquid–liquid phase separation and liquid-to-solid phase transition
- 13 October 2026
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 95, 102792
Effects of metal ions on amyloid liquid–liquid phase separation and liquid-to-solid phase transition
- Open Access
- 5 October 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (10) , 1659-1671
O2-Coupled Copper–Cysteine Redox Chemistry Drives Oxidative Modifications and Higher-Order Assembly of Monomeric Transthyretin
Copper–cysteine (Cu–Cys) coordination is pervasive in biology, yet how Cu–thiol redox chemistry engages O2 and translates into protein-level consequences remains incompletely understood. Here, we establish a generalizable protein-based platform that directly captures O2-coupled Cu(II)–Cys redox processes and delineates their structural and functional outcomes. Integrated spectroscopic, mass spectrometric, and computational investigations reveal that Cu(II) coordination to a protein Cys residue initiates redox cycling that generates thiyl radicals and/or disulfide radical anions. This chemically defined process drives disulfide bond formation together with O2-dependent oxidative transformations, producing site-specific Cys modifications, dityrosine cross-links, and higher-order protein assemblies. Under these conditions, these structural changes abolish the protein’s anti-amyloidogenic activity and result in apoptotic responses. By directly linking Cu–thiol redox chemistry to protein oxidation and aggregation, this work establishes a fundamental chemical principle by which redox-active metal ions govern protein fate under aerobic conditions. More broadly, these findings provide a mechanistic framework for understanding how metal-mediated oxidative chemistry contributes to protein misfolding and aggregation in human diseases.
- 5 October 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (10) , 1659-1671
Open AccessO2-Coupled Copper–Cysteine Redox Chemistry Drives Oxidative Modifications and Higher-Order Assembly of Monomeric Transthyretin
Copper–cysteine (Cu–Cys) coordination is pervasive in biology, yet how Cu–thiol redox chemistry engages O2 and translates into protein-level consequences remains incompletely understood. Here, we establish a generalizable protein-based platform that directly captures O2-coupled Cu(II)–Cys redox processes and delineates their structural and functional outcomes. Integrated spectroscopic, mass spectrometric, and computational investigations reveal that Cu(II) coordination to a protein Cys residue initiates redox cycling that generates thiyl radicals and/or disulfide radical anions. This chemically defined process drives disulfide bond formation together with O2-dependent oxidative transformations, producing site-specific Cys modifications, dityrosine cross-links, and higher-order protein assemblies. Under these conditions, these structural changes abolish the protein’s anti-amyloidogenic activity and result in apoptotic responses. By directly linking Cu–thiol redox chemistry to protein oxidation and aggregation, this work establishes a fundamental chemical principle by which redox-active metal ions govern protein fate under aerobic conditions. More broadly, these findings provide a mechanistic framework for understanding how metal-mediated oxidative chemistry contributes to protein misfolding and aggregation in human diseases.
- Open Access
- 30 September 2026
- Published by Wiley in Advanced Science
- p. e77886
Zinc Fingers as Programmable Metalloprotein Scaffolds for Altering Pathogenic Biomolecular Phase Transitions
Tunable control over biomolecular phase transitions provides a powerful blueprint for engineering functional soft materials, yet generalizable protein scaffolds capable of rewiring pathological condensates remain largely unexplored. Here, we demonstrate that zinc finger (ZF) proteins function as programmable interaction units that modulate neurodegenerative amyloid liquid–liquid phase separation, redirect β‐sheet‐rich fibrillation toward nontoxic assemblies, and actively disassemble preformed fibrils. Multiscale investigations spanning molecular, cellular, and organismal levels reveal that tandemly arrayed ZF modules mediate direct, high‐affinity protein–protein interactions, thereby mitigating amyloid pathogenicity. Through modular protein engineering, these protective effects translate in vivo, where a brain‐penetrant ZF variant reduces amyloid deposition, suppresses neuroinflammatory responses, and improves cognitive performance in Alzheimer's disease transgenic mice. Furthermore, sequence–structure–function analyses identify key determinants governing amyloid assembly control, offering mechanistic principles for ZF‐inspired protein engineering. Collectively, this work positions ZF proteins as versatile, chemically programmable platforms for engineering protein‐based materials that regulate biomolecular phase behavior and toxicity, expanding their functional scope beyond traditional genetic regulation toward therapeutic applications.
- 30 September 2026
- Published by Wiley in Advanced Science
- p. e77886
Open AccessZinc Fingers as Programmable Metalloprotein Scaffolds for Altering Pathogenic Biomolecular Phase Transitions
Tunable control over biomolecular phase transitions provides a powerful blueprint for engineering functional soft materials, yet generalizable protein scaffolds capable of rewiring pathological condensates remain largely unexplored. Here, we demonstrate that zinc finger (ZF) proteins function as programmable interaction units that modulate neurodegenerative amyloid liquid–liquid phase separation, redirect β‐sheet‐rich fibrillation toward nontoxic assemblies, and actively disassemble preformed fibrils. Multiscale investigations spanning molecular, cellular, and organismal levels reveal that tandemly arrayed ZF modules mediate direct, high‐affinity protein–protein interactions, thereby mitigating amyloid pathogenicity. Through modular protein engineering, these protective effects translate in vivo, where a brain‐penetrant ZF variant reduces amyloid deposition, suppresses neuroinflammatory responses, and improves cognitive performance in Alzheimer's disease transgenic mice. Furthermore, sequence–structure–function analyses identify key determinants governing amyloid assembly control, offering mechanistic principles for ZF‐inspired protein engineering. Collectively, this work positions ZF proteins as versatile, chemically programmable platforms for engineering protein‐based materials that regulate biomolecular phase behavior and toxicity, expanding their functional scope beyond traditional genetic regulation toward therapeutic applications.
- Open Access
- 29 September 2026
- Published by Elsevier in Cell Reports Physical Science
- Vol. 7 (10)
A glitazone-based chemical platform for mechanistic modulation of amyloid-β aggregation and associated pathology
- 29 September 2026
- Published by Elsevier in Cell Reports Physical Science
- Vol. 7 (10)
Open AccessA glitazone-based chemical platform for mechanistic modulation of amyloid-β aggregation and associated pathology
- 15 September 2026
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 13 (18) , 7593-7612
Reactivities of endocannabinoids toward metal-induced amyloid-β aggregation and oxidative stress associated with Alzheimer's disease
Endocannabinoids with metal-binding sites and amphiphilic properties alter metal–Aβ aggregation and control Cu( i / ii )- or Cu( i / ii )–Aβ-mediated ROS formation in a structure-dependent manner.
- 15 September 2026
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 13 (18) , 7593-7612
Reactivities of endocannabinoids toward metal-induced amyloid-β aggregation and oxidative stress associated with Alzheimer's disease
Endocannabinoids with metal-binding sites and amphiphilic properties alter metal–Aβ aggregation and control Cu( i / ii )- or Cu( i / ii )–Aβ-mediated ROS formation in a structure-dependent manner.
- 2 September 2026
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 126 (18) , 10249-10333
Metal Ions and Protein Aggregation: Unraveling Molecular Interactions and Theranostic Prospects in Proteinopathies
Protein aggregation is a pathological process associated with several human diseases termed proteinopathies, including neurodegenerative and metabolic disorders such as Alzheimer’s disease, Parkinson’s disease, type II diabetes, amyotrophic lateral sclerosis, and Huntington’s disease. In these conditions, specific proteins misfold and accumulate into insoluble aggregates, disrupting normal cellular function and contributing to disease progression. Many studies have investigated the molecular mechanisms that underlie the aggregation pathways, the structure of aggregates, such as oligomeric intermediates and fibrils, and their cellular toxicity. Studies have also investigated the effects of cofactors like metals, lipids, other amyloid proteins, and small molecules. Recent research has increasingly emphasized the critical roles of metal ions such as copper (Cu), zinc (Zn), iron (Fe), and manganese (Mn) in amyloid aggregation and toxicity. Alterations in metal ion transport, binding, or redox activity have been linked to the onset and progression of several amyloid-associated diseases. These metal ions can interact directly with amyloidogenic proteins, influencing their structural conformation, aggregation kinetics, and propensity to form toxic oligomers. This review aims to advance our understanding of how the regulation of metal ions within cells and their dysfunction contribute to the accumulation of harmful proteins, which is a key factor in proteinopathies. By examining the interactions between metal ions and key amyloidogenic proteins─including amyloid-β (Aβ), α-synuclein, tau, superoxide dismutase 1 (SOD1), human islet amyloid polypeptide (hIAPP), and insulin─we highlight both common and unique pathways through which metal ions influence protein aggregation. Additionally, this review explores the impact of metal ions on protein clearance mechanisms, such as autophagy and the ubiquitin–proteasome system, as well as emerging theranostic strategies. These include metal chelation therapies, metal-based imaging agents, and multifunctional compounds designed to restore metal balance while preventing aggregation and toxicity. By integrating biochemical, cellular, and therapeutic insights, this review contributes to a deeper understanding of the metallobiology of proteinopathies and supports the development of novel diagnostic and treatment approaches targeting metal–protein interactions.
- 2 September 2026
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 126 (18) , 10249-10333
Metal Ions and Protein Aggregation: Unraveling Molecular Interactions and Theranostic Prospects in Proteinopathies
Protein aggregation is a pathological process associated with several human diseases termed proteinopathies, including neurodegenerative and metabolic disorders such as Alzheimer’s disease, Parkinson’s disease, type II diabetes, amyotrophic lateral sclerosis, and Huntington’s disease. In these conditions, specific proteins misfold and accumulate into insoluble aggregates, disrupting normal cellular function and contributing to disease progression. Many studies have investigated the molecular mechanisms that underlie the aggregation pathways, the structure of aggregates, such as oligomeric intermediates and fibrils, and their cellular toxicity. Studies have also investigated the effects of cofactors like metals, lipids, other amyloid proteins, and small molecules. Recent research has increasingly emphasized the critical roles of metal ions such as copper (Cu), zinc (Zn), iron (Fe), and manganese (Mn) in amyloid aggregation and toxicity. Alterations in metal ion transport, binding, or redox activity have been linked to the onset and progression of several amyloid-associated diseases. These metal ions can interact directly with amyloidogenic proteins, influencing their structural conformation, aggregation kinetics, and propensity to form toxic oligomers. This review aims to advance our understanding of how the regulation of metal ions within cells and their dysfunction contribute to the accumulation of harmful proteins, which is a key factor in proteinopathies. By examining the interactions between metal ions and key amyloidogenic proteins─including amyloid-β (Aβ), α-synuclein, tau, superoxide dismutase 1 (SOD1), human islet amyloid polypeptide (hIAPP), and insulin─we highlight both common and unique pathways through which metal ions influence protein aggregation. Additionally, this review explores the impact of metal ions on protein clearance mechanisms, such as autophagy and the ubiquitin–proteasome system, as well as emerging theranostic strategies. These include metal chelation therapies, metal-based imaging agents, and multifunctional compounds designed to restore metal balance while preventing aggregation and toxicity. By integrating biochemical, cellular, and therapeutic insights, this review contributes to a deeper understanding of the metallobiology of proteinopathies and supports the development of novel diagnostic and treatment approaches targeting metal–protein interactions.
- Open Access
- 2 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (34) , 16541-16554
Metal–organic macrocycles as molecular modulators of amyloid-β aggregation and cytotoxicity
Rationally designed metal–organic macrocycles modulate amyloid-β aggregation through dual mechanisms involving direct peptide interactions and photoinduced oxidative modifications, resulting in reduced fibrillization and cytotoxicity.
- 2 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (34) , 16541-16554
Open AccessMetal–organic macrocycles as molecular modulators of amyloid-β aggregation and cytotoxicity
Rationally designed metal–organic macrocycles modulate amyloid-β aggregation through dual mechanisms involving direct peptide interactions and photoinduced oxidative modifications, resulting in reduced fibrillization and cytotoxicity.
- Open Access
- 5 June 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (28) , 14029-14040
Strategic physicochemical tuning: amphiphilic polymers as molecular regulators of amyloid aggregation and cytotoxicity
Amyloidogenesis is a central pathological process in neurodegenerative disorders, yet general chemical principles that enable its predictive control are still insufficiently understood. Synthetic polymers offer a versatile and chemically tunable platform for modulating amyloid assembly; however, quantitative relationships linking polymer physicochemical properties to amyloidogenic pathways and biological outcomes remain poorly established. Here we present a systematic and quantitative framework that connects polymer composition to amyloid reactivity. By precisely tuning hydrophobicity, hydrophilicity, and net charge, and integrating polymer synthesis with computational, biochemical, and cellular analyses, we uncover clear structure–activity relationships governing interactions with amyloidogenic peptides and proteins, such as amyloid-β and α-synuclein. We show that balanced amphiphilic architectures, particularly hydrophobic–zwitterionic compositions, suppress fibrillization, redirect aggregation pathways, and reduce cellular membrane association, thereby attenuating cytotoxicity. In contrast, cationic-rich polymers promote aggregation via electrostatically driven mechanisms, while hydrophobic-dominant polymers exhibit minimal regulatory effects. Importantly, these composition-dependent behaviors are conserved across distinct amyloid systems, establishing a generalizable physicochemical framework in which the interplay between amphiphilicity and charge dictates amyloid reactivity and cellular responses. Overall, this work provides design principles for polymer-based chemical modulators and a broadly applicable strategy for controlling protein aggregation in neurodegenerative disease contexts.
- 5 June 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (28) , 14029-14040
Open AccessStrategic physicochemical tuning: amphiphilic polymers as molecular regulators of amyloid aggregation and cytotoxicity
Amyloidogenesis is a central pathological process in neurodegenerative disorders, yet general chemical principles that enable its predictive control are still insufficiently understood. Synthetic polymers offer a versatile and chemically tunable platform for modulating amyloid assembly; however, quantitative relationships linking polymer physicochemical properties to amyloidogenic pathways and biological outcomes remain poorly established. Here we present a systematic and quantitative framework that connects polymer composition to amyloid reactivity. By precisely tuning hydrophobicity, hydrophilicity, and net charge, and integrating polymer synthesis with computational, biochemical, and cellular analyses, we uncover clear structure–activity relationships governing interactions with amyloidogenic peptides and proteins, such as amyloid-β and α-synuclein. We show that balanced amphiphilic architectures, particularly hydrophobic–zwitterionic compositions, suppress fibrillization, redirect aggregation pathways, and reduce cellular membrane association, thereby attenuating cytotoxicity. In contrast, cationic-rich polymers promote aggregation via electrostatically driven mechanisms, while hydrophobic-dominant polymers exhibit minimal regulatory effects. Importantly, these composition-dependent behaviors are conserved across distinct amyloid systems, establishing a generalizable physicochemical framework in which the interplay between amphiphilicity and charge dictates amyloid reactivity and cellular responses. Overall, this work provides design principles for polymer-based chemical modulators and a broadly applicable strategy for controlling protein aggregation in neurodegenerative disease contexts.
- Open Access
A Prodrug Approach for Activity‐Based Chemical Modulation toward Multiple Pathological Targets in Alzheimer's Disease
Targeting disease‐specific chemical signals enables precise therapeutic control over complex pathologies. In Alzheimer's disease (AD), elevated hydrogen peroxide (H 2 O 2 ) accompanies hallmark features, including amyloid‐β (Aβ) aggregate deposition and metal ion dyshomeostasis, creating an oxidative milieu primed for selective chemical activation. Here, we show a rationally designed prodrug platform that harnesses H 2 O 2 as an endogenous trigger for redox‐based therapy. Boronic ester‐masked precursors ( BE‐1 and BE‐2 ) remain inert under physiological conditions but undergo rapid oxidative deboronation in the presence of H 2 O 2 , releasing redox‐active aminophenols. These activated molecules exhibit multimodal pathological modulation, as revealed by molecular‐level biochemical and biophysical analyses: scavenging reactive oxygen species, inducing residue‐specific oxidative modifications of Aβ, and redirecting aggregation pathways of both metal‐free and metal‐bound Aβ. In AD transgenic mice, BE‐1 undergoes conversion to its active form within the brain tissue. Long‐term administration of BE‐1 markedly reduces hippocampal oxidative stress, lowers amyloid plaque burden, and improves cognitive performance. This pathology‐responsive, activity‐based prodrug strategy provides a chemically precise framework for simultaneously modulating multiple, interconnected drivers of neurodegeneration.
Open AccessA Prodrug Approach for Activity‐Based Chemical Modulation toward Multiple Pathological Targets in Alzheimer's Disease
Targeting disease‐specific chemical signals enables precise therapeutic control over complex pathologies. In Alzheimer's disease (AD), elevated hydrogen peroxide (H 2 O 2 ) accompanies hallmark features, including amyloid‐β (Aβ) aggregate deposition and metal ion dyshomeostasis, creating an oxidative milieu primed for selective chemical activation. Here, we show a rationally designed prodrug platform that harnesses H 2 O 2 as an endogenous trigger for redox‐based therapy. Boronic ester‐masked precursors ( BE‐1 and BE‐2 ) remain inert under physiological conditions but undergo rapid oxidative deboronation in the presence of H 2 O 2 , releasing redox‐active aminophenols. These activated molecules exhibit multimodal pathological modulation, as revealed by molecular‐level biochemical and biophysical analyses: scavenging reactive oxygen species, inducing residue‐specific oxidative modifications of Aβ, and redirecting aggregation pathways of both metal‐free and metal‐bound Aβ. In AD transgenic mice, BE‐1 undergoes conversion to its active form within the brain tissue. Long‐term administration of BE‐1 markedly reduces hippocampal oxidative stress, lowers amyloid plaque burden, and improves cognitive performance. This pathology‐responsive, activity‐based prodrug strategy provides a chemically precise framework for simultaneously modulating multiple, interconnected drivers of neurodegeneration.
- 4 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (6) , 9285-9307
Chemical Strategies to Modulate Amyloidogenesis Associated with Neurodegenerative Diseases
Amyloidogenic peptides and proteins, including amyloid-β, tau, and α-synuclein, are key pathological factors in neurodegenerative diseases. Their misfolding and self-assembly into toxic oligomers and fibrils disrupt cellular homeostasis and lead to neuronal dysfunction. To address these pathogenic processes, diverse chemical strategies have been developed employing nanomaterials, small organic molecules, and metal complexes. These reagents chemically modify amyloidogenic peptides and proteins, thereby altering their aggregation pathways, attenuating associated toxicity, and demonstrating in vivo efficacy. In this review, we outline and discuss the design principles and mechanistic bases of these chemical interventions, with some examples that demonstrate anti-amyloidogenic effects. Collectively, these advances underscore the power of chemistry to modulate amyloid aggregation and provide mechanistic insights that can guide the development of innovative therapeutic strategies for amyloid-driven neurodegeneration.
- 4 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (6) , 9285-9307
Chemical Strategies to Modulate Amyloidogenesis Associated with Neurodegenerative Diseases
Amyloidogenic peptides and proteins, including amyloid-β, tau, and α-synuclein, are key pathological factors in neurodegenerative diseases. Their misfolding and self-assembly into toxic oligomers and fibrils disrupt cellular homeostasis and lead to neuronal dysfunction. To address these pathogenic processes, diverse chemical strategies have been developed employing nanomaterials, small organic molecules, and metal complexes. These reagents chemically modify amyloidogenic peptides and proteins, thereby altering their aggregation pathways, attenuating associated toxicity, and demonstrating in vivo efficacy. In this review, we outline and discuss the design principles and mechanistic bases of these chemical interventions, with some examples that demonstrate anti-amyloidogenic effects. Collectively, these advances underscore the power of chemistry to modulate amyloid aggregation and provide mechanistic insights that can guide the development of innovative therapeutic strategies for amyloid-driven neurodegeneration.